
Freedom Biosciences achieved a major $10.5 million in a seed financing round in which MBX Capital, PsyMed Ventures, Village Global and The Yale Startup, among others, participated.
The clinical-stage biotech company, which develops therapeutics based on various psychedelics to treat major depressive disorder, will use the funds to advance its lead ketamine program as well as other exploratory programs under the leadership of cofounder Dr. John Krystal, who presides over the psychiatry department at Yale University. Krystal has extensive experience working with ketamine for depression treatment.